Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04945642 · ClinicalTrials.gov registry record · NA
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
A NA study of Prostate Adenocarcinoma and Stage III Prostate Cancer AJCC v8, sponsored by Jonsson Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT04945642 is a NA study of Prostate Adenocarcinoma and Stage III Prostate Cancer AJCC v8 that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 52 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04945642, a NA study of Prostate Adenocarcinoma and Stage III Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.
Conditions Studied
Interventions
- RADIATION Stereotactic Body Radiation Therapy
- RADIATION High-Dose Rate Brachytherapy
Study Locations (1)
California
- University of California at Los Angeles / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-08-20 |
| Est. Completion | 2027-07-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04945642
The ClinicalTrials.gov registry entry for NCT04945642 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (76% lower). The listed sponsor is Jonsson Comprehensive Cancer Center, which has 321 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Stereotactic Body Radiation Therapy is the first listed.
NCT04945642 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04945642 about?
NCT04945642 is a clinical study titled "High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma". This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma. Brachytherapy, also known as internal radiation therapy, uses radioactive material placed directly into or near a tumor to kill tumor cell...
What is the current status of trial NCT04945642?
This trial is currently recruiting. It is a NA study. The enrollment target is 52 participants. The study started on 2021-08-20. Estimated completion is 2027-07-01.
What conditions does trial NCT04945642 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8.
What interventions are being tested in trial NCT04945642?
The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), High-Dose Rate Brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT04945642?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04945642 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
RECRUITING · NA
-
The Use of Ultrasound in Assessing Post-prostatectomy Erectile Dysfunction
RECRUITING · NA
-
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
RECRUITING · NA
-
Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement
RECRUITING · NA
-
Two-fraction HDR Monotherapy for Localized Prostate Cancer
RECRUITING · NA
-
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
RECRUITING · NA
Explore more on PlainTrial
Prostate Adenocarcinoma
All registered trials for this condition
Stage III Prostate Cancer AJCC v8
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.